Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)

被引：7
|
作者：
Leonard, R
Miles, D
Reichardt, P
Twelves, C
机构：
[1] S Wales Canc Inst, Swansea, W Glam, Wales
[2] Guys & St Thomas Hosp, London SE1 9RT, England
[3] HELIOS Klinikum, Dept Hematol Oncol & Tumorimmunol, Berlin, Germany
[4] Univ Leeds, Leeds LS2 9JT, W Yorkshire, England
[5] Bradford Royal Infirm, Bradford BD9 6RJ, W Yorkshire, England
来源：
SEMINARS IN ONCOLOGY | 2004年 / 31卷 / 05期
关键词：
D O I：
10.1053/j.seminoncol.2004.07.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：21 / 28
页数：8
相关论文
共 50 条
  • [21] EVOLUTION OF CHEMOTHERAPY OPTIONS IN HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Verma, S.
    Zielinski, C.
    Martin, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 99
  • [22] Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
    Dhakal, Ajay
    O'Regan, Ruth
    Falkson, Carla
    Hicks, David
    Hawkins, Douglas
    Turner, Bradley
    Mohile, Nimish
    CANCER RESEARCH, 2023, 83 (05)
  • [23] SAFETY AND EFFICACY OF MAINTENANCE BEVACIZUMAB IN HER2-NEGATIVE METASTATIC BREAST CANCER
    Russillo, M.
    Metro, G.
    Giannarelli, D.
    Papaldo, P.
    Nistico, C.
    Ferretti, G.
    Cuppone, F.
    D'Auria, G.
    Cognetti, F.
    Fabi, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 105 - 105
  • [24] Photoeruption in a patient treated with capecitabine (Xeloda) for metastatic breast cancer
    Willey, A
    Glusac, EJ
    Bolognia, JL
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (03) : 453 - 453
  • [25] Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: Response, survival, and prognostic factors
    Gilabert, M.
    Esterni, B.
    Bertucci, F.
    Viens, P.
    Goncalves, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Masataka Yoshimoto
    Shintaro Takao
    Masaru Hirata
    Yasushi Okamoto
    Sumio Yamashita
    Yoshihiro Kawaguchi
    Makoto Takami
    Hidemi Furusawa
    Satoshi Morita
    Chigusa Abe
    Junichi Sakamoto
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 331 - 338
  • [27] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Yoshimoto, Masataka
    Takao, Shintaro
    Hirata, Masaru
    Okamoto, Yasushi
    Yamashita, Sumio
    Kawaguchi, Yoshihiro
    Takami, Makoto
    Furusawa, Hidemi
    Morita, Satoshi
    Abe, Chigusa
    Sakamoto, Junichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 331 - 338
  • [28] Capecitabine after Anthracycline and Taxane Exposure in HER2-negative Metastatic Breast Cancer Patients: Response, Survival and Prognostic Factors
    Gilaberti, Marine
    Bertucci, Francois
    Esterni, Benjamin
    Madroszyk, Anne
    Tarpin, Carole
    Jacquemier, Jocelyne
    Extra, Jean-Marc
    Viens, Patrice
    Goncalves, Anthony
    ANTICANCER RESEARCH, 2011, 31 (03) : 1079 - 1086
  • [29] When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
    Miles, David W.
    BREAST CANCER RESEARCH, 2009, 11 (04)
  • [30] Optimizing the Management of Metastatic HER2-Positive Breast Cancer
    Goel S.
    Tolaney S.
    Current Breast Cancer Reports, 2015, 7 (4) : 190 - 202
12345